Connor, Clark & Lunn Investment Management (CC&L)
AMED

Connor, Clark & Lunn Investment Management (CC&L)’s Amedisys AMED Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-22,338
Closed -$5.47M – 1025
2021
Q2 		$5.47M Buy
22,338
+7,853
+54% +$2.06M 0.03% 337
2021
Q1 		$3.83M Buy
14,485
+2,568
+22% +$724K 0.02% 420
2020
Q4 		$3.5M Sell
11,917
-1,930
-14% -$495K 0.02% 405
2020
Q3 		$3.27M Buy
13,847
+9,619
+228% +$2.19M 0.02% 379
2020
Q2 		$839K Buy
+4,228
New +$789K 0.01% 654
2019
Q4 		– Sell
-8,025
Closed -$1.05M – 917
2019
Q3 		$1.05M Sell
8,025
-23,525
-75% -$3.06M 0.01% 535
2019
Q2 		$3.83M Buy
31,550
+8,325
+36% +$988K 0.02% 326
2019
Q1 		$2.86M Buy
23,225
+15,425
+198% +$1.94M 0.02% 357
2018
Q4 		$913K Buy
7,800
+3,975
+104% +$469K 0.01% 569
2018
Q3 		$478K Buy
+3,825
New +$422K ﹤0.01% 713
2016
Q2 		– Sell
-15,775
Closed -$763K – 861
2016
Q1 		$763K Sell
15,775
-42,350
-73% -$1.63M 0.01% 504
2015
Q4 		$2.29M Sell
58,125
-61,025
-51% -$2.44M 0.02% 312
2015
Q3 		$4.52M Sell
119,150
-34,350
-22% -$1.45M 0.04% 213
2015
Q2 		$6.1M Sell
153,500
-21,700
-12% -$676K 0.06% 139
2015
Q1 		$4.69M Sell
175,200
-45,900
-21% -$1.29M 0.04% 157
2014
Q4 		$6.49M Sell
221,100
-21,900
-9% -$541K 0.05% 141
2014
Q3 		$4.9M Sell
243,000
-7,800
-3% -$150K 0.04% 138
2014
Q2 		$4.47M Sell
250,800
-16,500
-6% -$234K 0.03% 166
2014
Q1 		$4.39M Buy
267,300
+41,700
+18% +$642K 0.03% 174
2013
Q4 		$3.51M Buy
225,600
+60,200
+36% +$969K 0.03% 195
2013
Q3 		$2.93M Buy
165,400
+50,000
+43% +$742K 0.03% 159
2013
Q2 		$1.41M Buy
+115,400
New +$1.32M 0.01% 230

Other funds holding AMED

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s AMED Position: Q3 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Amedisys (AMED) in Q3 2021, closing a stake of 22,338 shares — an estimated $5.47M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AMED in Q2 2013 and held it in 22 quarters. The position peaked at $6.49M in Q4 2014. 352 funds tracked by Wall St. Rank hold AMED as of Q3 2021.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Amedisys position as of Q3 2021 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 22,338 Amedisys shares in Q3 2021, an estimated $5.47M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Amedisys in Q2 2013 and held it in 22 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Amedisys position peaked at $6.49M in Q4 2014.
  • 352 funds tracked by Wall St. Rank held Amedisys as of Q3 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2021, filed 12 Nov 2021.